Latest News

CanalLotus Biotech news and insights

FDA Approves Juvmo (tavapadon) for the Treatment of Parkinson's Disease

NORTH CHICAGO, Ill., Sept. 28, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved Juvmo (tavapadon) tablets as the first and only se

Latest News NDA News 353
• Read All

FDA Approves Atebrioz (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE) September 25, 2026 -- Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Adminis

Latest News NDA News 294
• Read All

FDA Approves Degevma (denosumab-adet), a Biosimilar to Xgeva

TEL AVIV, Israel, and PARSIPPANY, N.J., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) ha

Latest News NDA News 289
• Read All

FDA Approves Lamlique (lamotrigine) Oral Suspension for Seizures and Bipolar Disorder

September 29, 2026 -- Azurity Pharmaceuticals, a privately held global pharmaceutical company dedicated to redefining medicine for the real world, today announced that the U.S. Food and Drug Administr

Latest News NDA News 267
• Read All

FDA Approves Onswik (insulin efsitora alfa-gobe) Once-Weekly Basal Insulin for Adults with Type 2 Diabetes

INDIANAPOLIS, Sept. 24, 2026 /PRNewswire/ -- Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) approval of Onswik (insulin efsitora alfa-gobe), a once-weekly basal insu

Latest News NDA News 331
• Read All

FDA Approves Lyrfigtu (lirafugratinib) for the Treatment of Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement

FORT LEE, N.J., September 23, 2026 -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experien

Latest News NDA News 313
• Read All

FDA Approves Bravnetsa (lutetium Lu 177 dotatate) as a Therapeutic Equivalent to Lutathera for the Treatment of Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors in Adults

BEDFORD, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed t

Latest News NDA News 277
• Read All

FDA Approves Fayuvi (rebisufligene etisparvovec-hopf) Gene Therapy for the Treatment for Sanfilippo Syndrome Type A (MPS IIIA)

NOVATO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the U.S. Food and Drug Administration (FDA) granted standard full approval of Fayu

Latest News NDA News 431
• Read All

FDA Approves Bexlutry (lutetium Lu 177 dotatate) for Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors

Boston, MA – 14 September, 2026 -- Curium™ announced today that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Bexlutry™ lutetium Lu 177 dotatate injection

Latest News NDA News 436
• Read All

FDA Approves Pixclara (floretyrosine F 18) FET-PET Imaging Agent for Glioma

Melbourne (Australia) and Indianapolis, IN (United States) -- September 14, 2026 -- Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug App

Latest News NDA News 381
• Read All

FDA Approves Isembyld (apitegromab-mstn) Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)

CAMBRIDGE, Mass.--(BUSINESS WIRE) -- September 11, 2026 -- Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitat

Latest News NDA News 422
• Read All

FDA Grants Accelerated Approval to Etcamah (camizestrant) in Combination with a CDK4/6 Inhibitor for the Treatment of Advanced HR-Positive Breast Cancer

September 4, 2026 -- AstraZeneca’s Etcamah (camizestrant) in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (abemaciclib, palbociclib or ribociclib) has been approved in the US for the

Latest News NDA News 422
• Read All
News
Gloved hands holding a globe, global clinical trial drug sourcing
- CanalLotus Biotech -
Int'l Clinical Service Expert

We are the leader
Because of our professionism

WhatsApp Service QR code